Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.

Oncotarget - 6 Oct 2015

Pellegrini Camilla, Columbaro Marta, Capanni Cristina, D'Apice Maria Rosaria, Cavallo Carola, Murdocca Michela, Lattanzi Giovanna, Squarzoni Stefano

Abstract excerpt

Hutchinson Gilford progeria syndrome is a fatal disorder characterized by accelerated aging, bone resorption and atherosclerosis, caused by a LMNA mutation which produces progerin, a mutant lamin A precursor. Progeria cells display progerin and prelamin A nuclear accumulation, altered histone methylation pattern, heterochromatin loss, increased DNA damage and cell cycle alterations. Since the LMNA promoter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Lamin Type A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microscopy, Electron, Transmission

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerases

Share to Progeria

Share to Sirolimus

Share to Tretinoin

Source

Open in PubMed Open full text

Identifiers

PMID: 26359359
DOI: 10.18632/oncotarget.4939
PMCID: PMC4745772

Genes

LMNA
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.PMID 26359359Read ↗

An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.Semantic proximity Read ↗

Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype.Semantic proximity Read ↗

Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.Semantic proximity Read ↗

Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy TreatmentSemantic proximity Read ↗

Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.Semantic proximity Read ↗

Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach.Semantic proximity Read ↗

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes.Semantic proximity Read ↗

Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.Semantic proximity Read ↗

Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.Semantic proximity Read ↗

Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.Semantic proximity Read ↗

Progerin, an Aberrant Spliced form of Lamin A, is a Potential Therapeutic Target for HGPSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.